1. Home
  2. MIRM vs FCNCP Comparison

MIRM vs FCNCP Comparison

Compare MIRM & FCNCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$77.57

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Logo First Citizens BancShares Inc.

FCNCP

First Citizens BancShares Inc.

HOLD

Current Price

$20.42

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
FCNCP
Founded
2018
N/A
Country
United States
United States
Employees
N/A
17475
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
N/A
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MIRM
FCNCP
Price
$77.57
$20.42
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
$92.45
N/A
AVG Volume (30 Days)
844.6K
N/A
Earning Date
11-04-2025
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$471,794,000.00
N/A
Revenue This Year
$53.78
N/A
Revenue Next Year
$19.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
53.66
N/A
52 Week Low
$36.88
N/A
52 Week High
$82.58
N/A

Technical Indicators

Market Signals
Indicator
MIRM
FCNCP
Relative Strength Index (RSI) 58.25 40.91
Support Level $77.99 $19.97
Resistance Level $82.58 $20.50
Average True Range (ATR) 3.33 0.33
MACD 0.71 0.03
Stochastic Oscillator 74.62 36.18

Price Performance

Historical Comparison
MIRM
FCNCP

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About FCNCP First Citizens BancShares Inc.

First Citizens BancShares Inc is the bank holding company of First Citizens Bank and Trust Company. The company's segments include the General Bank, the Commercial Bank, SVB Commercial, and Rail. The General Bank segment delivers products and services to consumers and businesses through its extensive network of branches and various digital channels. The Commercial Bank segment provides financial services, including lending, leasing, and advisory, to small and mid-market businesses across various industries. The SVB Commercial provides financial services to innovators, investors, and venture firms. The Rail segment provides tailored leasing and financing for railcars and locomotives across North America. It generates the majority of its revenue from the General Banking segment.

Share on Social Networks: